PharmatecaPharmatecaФарматека2073-40342414-9128Bionika Media287926ArticlesСтатьиResearch ArticleKOMPLEKSNAYa TERAPIYa HER2-POZITIVNOGO RAKA MOLOChNOY ZhELEZYКОМПЛЕКСНАЯ ТЕРАПИЯ HER2-ПОЗИТИВНОГО РАКА МОЛОЧНОЙ ЖЕЛЕЗЫSemiglazovV. FСемиглазовВ. Ф

д.м.н., проф., заслуженный деятель науки, член-корр. РАН, зав. научным отделением опухолей молочной железы, гл.н.с.

vsemiglazov@mail.ruSemiglazovV. VСемиглазовВ. В

д.м.н., зав. кафедрой онкологии

ssemiglazov@mail.ruNikolaevK. SНиколаевК. С

врач-онколог хирургического отделения опухолей молочной железы

kirill.nikolaev87@gmail.comDashyanG. AДашянГ. А

д.м.н., в.н.с. отделения опухолей молочной железы

dgarik@mail.ruPaltuevR. MПалтуевР. М

зам. глав. врача по специализированной медицинской помощи

paltuev@mail.ruФГБУ НИИ онкологии им. Н.Н. Петрова МЗ РФСанкт-Петербургский государственный медицинский университет им. акад. И.П. Павлова МЗ РФНУЗ «Дорожная клиническая больница» ОАО РЖД20042015228NO8 (2015)№8 (2015)213126022023Copyright ©; 2015, Bionika MediaCopyright ©; 2015, ООО «Бионика Медиа»2015Bionika MediaООО «Бионика Медиа»https://journals.eco-vector.com/2073-4034/article/view/287926

Is the most significant advance in the treatment of this disease, because it changes the natural course of breast cancer. However, resistance to anti-HER2 drugs is an important clinical problem both at early and advanced stages of disease; therefore, there is a need for new therapeutic approaches. The article presents the clinical data on HER2-targeted drugs that are under development or already in use in clinical practice.

НЕR2-позитивный рак молочной железы представляет собой молекулярный подтип заболевания с агрессивным биологическим и клиническим «поведением». Трастузумаб революционировал лечение этого заболевания, изменив его естественное течение. Однако резистентность к анти-HER2-препаратам представляет собой важную клиническую проблему, встречаясь как при ранних, так и при распространенных стадиях заболевания; поэтому необходимы новые лечебные подходы. В статье представлены клинические данные о HER2-направленных препаратах, находящихся в разработке или уже используемых в клинической практике.

HER2-positive breast canceranti-HER2 therapy: adjuvant therapyneoadjuvant therapy and therapy of metastatic formsHER2-позитивный рак молочной железыанти-HER2-терапия: адъювантнаянеоадъювантная и метастатических формЖукова Л.Г., Личиницер М.Р. Адъювантная терапия трастузумабом при ранних стадиях рака молочной железы: 12 или 24 месяца (по данным ESMO, Вена, октябрь 2012). Фарматека. 2012;18:69-70.Семиглазов В.Ф., Семиглазов В.В., Манихас А. Г. Рак молочной железы. Химиотерапия и таргетная терапия. М., 2012. 360 с.Семиглазов В.Ф., Манихас А.Г., Семиглазова Т.Ю., Бессонов А.А., Семиглазов В.В. Неоадъювантная системная терапия рака молочной железы: Руководство. СПб., 2012. 112 с.Goldhirsch A. Personalized adjuvant therapies: lessons from the past. The Breast. 2013;22:S.1(abst. 01).Goldhirsch A., Gelber R.D., Piccart-Gebhart M.J., de Azambuja E., Procter M., Suter T.M., Jac-kisch C., Cameron D., Weber H.A., Heinzmann D., Dal Lago L., McFadden E., Dowsett M., Untch M., Gianni L., Bell R., Köhne C.H., Vindevoghel A., Andersson M., Brunt A.M., Otero-Reyes D., Song S., Smith I., Leyland-Jones B., Baselga J.; Herceptin Adjuvant (HERA) Trial Study Team. HERA TRIAL: 2 years versus 1 year of trastuzumab after adjuvant chemotherapy in women with HER2-positive early breast cancer at 8 years of median follow up. Cancer Res. 2013;(24):103.De Cock E., Knoop A., Jakobsen E.H., et al. Manual injection of subcutaneous trastuzumab vs intravenous infusion for HER2-positive early breast cancer. European Cancer Congress, 27 September - 1 October 2013. Amsterdam. Abstract 128.Горбунова В.А. Новые перспективные препараты для лечения HER2-позитивного рака молочной железы. Фарматека. 2014;8:19-28.Семиглазов В.Ф., Семиглазов В.В. Четыре аспекта адъюватной таргетной терапии HER2-позитивного рака молочной железы. Фарматека. 2013;8:10-4.Chia S., Norris B., Speers C., Cheang M., Gilks B., Gown A.M., Huntsman D., Olivotto I.A., Nielsen T.O., Gelmon K. Human epidermal growth factor receptor 2 overexpression as a prognostic factor in a large tissue microarray series of node-negative breast cancers. JCO. 2008;26:5697-704.Gianni L., Eiermann W., Semiglazov V., Manikhas A., Lluch A., TjulandinS., Zambetti M., Vazquez F., Byakhow M., Lichinitser M., Climent M.A., Ciruelos E., Ojeda B., Mansutti M., Bozhok A., Baronio R., Feyereislova A., Barton C., Valagussa P., Baselga J. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomized controlled superiority trial with a parallel HER2-negative cohort. Lancet. 2010;375:377-84.Gianni L., Eiermann W., Semiglazov V., Lluch A., Tjulandin S., Zambetti M., Moliterni A., Vazquez F., Byakhov M.J., Lichinitser M., Climent M.A., Ciruelos E., Ojeda B., Mansutti M., Bozhok A., Magazzu D., Heinzmann D., Steinseifer J., Valagussa P., Baselga J. Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomized controlled superiority trial with a parallel HER2-negative cohort. Lancet Oncol. 2014;379:377-78.Molina M., Codony-Servat J., Albanell J., Rojo F., Arribas J., Baselga J. Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells. Cancer Res. 2001;61(12):4744-49.Agus D., Akita R., Fox W., Lewis G.D., Higgins B., Pisacane P.I., Lofgren J.A., Tindell C., Evans D.P., Maiese K., Scher H.I., Sliwkowski M.X. Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. Cancer Cell. 2002;2:127-37.Scheuer W., Friess T., Burtscher H., Bossenmaier B., Endl J., Hasmann M. Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models. Cancer Res. 2009;69:9330-36.Baselga J., Gelmon K., Verma S., Wardley A., Conte P., Miles D., Bianchi G., Cortes J., McNally V.A., Ross G.A., Fumoleau P., Gianni L. Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy. J. Clin. Oncol. 2010;28:1138-44.Gianni L., Pienkowski T., Im Y.-H., Roman L., Tseng L.M., Liu M.C., Lluch A., Staroslawska E., de la Haba-Rodriguez J., Im S.A., Pedrini J.L, Poirier B., Morandi P., Semiglazov V., Srimuninnimit V., Bianchi G., Szado T., Ratnayake J., Ross G., Valagussa P. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol. 2012;13:25-32.Gluck S., McKenna E., Royce M. Capecitabine plus docetaxel, with or without trastuzumab, as preoperative therapy for early breast cancer. Int. Med. Sci. 2008;5:341-46.Baselga J., Bradbury I., Eidtmann H., Cosimo S., de Azambuja E., Aura C., Gomez H., Dinh P., Fauria K., Van Dooren V., Aktan G., Goldhirsch A., Chang T.W., Horvath Z., Coccia-Portugal M., Domont J., Tseng L.M., Kunz G., Sohn J.H., Semiglazov V., Lerzo G., Palacova M., Probachai V., Pusztai L., Untch M., Gelber R.D., Piccart-Gebhart M. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. Lancet. 2012; 379:633-40.Untch M., Rezai M., Loibl S. Neoadjuvant treatment of HER2 overexpressing primary breast cancer with trastuzumab given concomitantly to epirubicin/cyclophosphamidr followed by docetaxel/capecitabine: first analysis of efficacy and safety of the GBG. AGO multicenter intergroup-study «GeparQuattro» (abstr. 1LB). European Breast Cancer Conference, April 15-19. Berlin, Germany, 2008.Portera C.C., WalsheJ.M.,RosingD.R, Denduluri N, Berman A.W., Vatas U., Velarde M., ChowC.K, SteinbergS.M.,NguyenD., YangS.X., Swain S.M. Cardiac toxicity and efficacy of trastuzumab combined with pertuzumab in patients with (corrected) human epidermal growth factor receptor 2-positive metastatic breast cancer. Clin. Cancer Res. 2008;14:2710-16.Baselga J., Cortes J., Kim S.-B., Im S.A., Hegg R., Im Y.H., Roman L., Pedrini J.L., Pienkowski T., Knott A., Clark E., Benyunes M.C., Ross G., Swain S.M.; CLEOPATRA Study Group. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N. Engl. J. Med. 2012;366:109-19.Lenihan D., Suter T., Brammer M., Neate C., Ross G., Baselga J. Pooled analysis of cardiac safety in patients with cancer treated with pertuzumab. Ann Oncol. 2012;23:791-800.Baselga J., Cortes J., Im S.A., Clark E., Ross G., Kiermaier A., Swain S.M. Biomarker analyses in CLEOPATRA: A phase III, placebo-controlled study of pertuzumab in HER2-positive, first-line metastatic breast cancer (MBC). In: Abstracts: Thirty-Fifth Annual CTRC-AACR San Antonio Breast Cancer Symposium. San Antonio, TX: American Association for Cancer Research, 2012. P. 5-1.Swain S.M., Kim S., Cortes J., et al. Confirmatory overall survival (OS) analysis of CLEOPATRA: a randomized, double-blind, placebo- controlled phase !!! study with pertuzumab (P), trastuzumab (T), and docetaxel (D) in patients (pts) with HER2-positive first-line (1L) metastatic breast cancer (MBS). San Antonio Breast Cancer Symposium. 2012;(Abstr.):5-18-26.Swain S.M., Kim S.B., Cortes J., Semiglazov V., Campone M., Ciruelos E., Ferrero J.M., Schneeweiss A., Knott A., Clark E., Ross G., Benyunes M.C., Baselga J. Pertuzumab, trastuzumab, and docetaxel for HER2 - positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomized, double-blind, placebo-controlled, phase 3 study. Lancet Oncol. 2013;14:461-71.Swain S.M., Ewer M.S., Cortes J., Amadori D., Miles D., Knott A., Clark E., Benyunes M.C., Ross G., Baselga J. Cardiac tolerability of pertuzumab plus trastuzumab plus docetaxel in patients with HER2-positive metastatic breast cancer in CLEOPATRA: a randomized, double-blind, placebo-controlled phase !!! study. Oncologist 2013;18:257-64.Schneeweiss A., Chia S., Hickish T., et al. Neoadjuvant pertuzumab and trastuzumab concurrent or sequential with an anthracyclinecontaining or concurrent with an anthra-cycline-free standard regimen: a randomized phase I! study (TRYPHAENA). Cancer Res. 2011;71(Suppl 24):112.Erickson H.K., Park P.U., Widdison W.C., Kovtun Y.V., Garrett L.M., Hoffman K., Lutz R.J., Goldmacher V.S., Blättler W.A. Antibody-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing. Cancer Res. 2006;66:4426-33.Lewis Phillips G.D., Li G., Dugger D.L., Crocker L.M., Parsons K.L., Mai E., Blättler W.A., Lambert J.M., Chari R.V., Lutz R.J., Wong W.L., Jacobson F.S., Koeppen H., Schwall R.H., Kenkare-Mitra S.R., Spencer S.D., Sliwkowski M.X. Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Res. 2008;68: 9280-90.Krop !.E., Beeram M., Modi S., Jones S.F., Holden S.N., Yu W., Girish., Tibbitts J., Yi J.H., Sliwkowski M.X., Jacobson F., Lutzker S.G., Burris H.A. Phase ! study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer. J. Clin. Oncol. 2010;28:2698-704.Verma S.,Miles D.,GianniL.,Kropl E., Welslau M., Baselga J., Pegram M., Oh D.Y., Dieras V., Guardino E., Fang L., Lu M.W., Olsen S., Blackwell K.; EMILIA Study Group. Trastuzumab emtansine for HER2-positive advanced breast cancer. N. Engl. J. Med. 2012;367:1783-91.Kropl E., Kim S., Gonzalez-Martin A., LoRusso P.M., Ferrero J-M., Smitt M., Yu R., Leung A.C.F., Wildiers H. Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2 - positive advanced breast cancer (TH3RESA): a randomized, open-label, phase 3 trial. Lancet Oncol. 2014;15:689-99.Burste in H.J., Sun Y., Dirix L.Y., Jiang Z., Paridaens R., Tan A.R., Awada A., Ranade A., Jiao S., Schwartz G., Abbas R., Powell C., Turnbull K., Vermette J., Zacharchuk C., Badwe R. Neratinib, an irreversible ErbB receptor tyro sine kinase inhibitor, in patients with advanced ErbB2 positive breast cancer. J. Clin. Oncol. 2010;l(28):1301-307.Swaby R., Blackwell K.L. Neratinib in combination with trastuzumab for the treatment of advanced breast cancer: A phase I/II study. J. Clin. Oncol. 2009;27(15):abstr 1004.Hickish T., Wheatley D., Lin N., et al. Use of B!BW 2992, a novel irreversible EGFR/HER 1 and HER2 tyrosine kinase inhibitor to treat patients with HER2-positive metastatic breast cancer after failure of treatment with trastu-zumab. Cancer Res. 2010;69:5060-0.Berns K., Horlings H.M., Hennessy В.Т., Madiredjo M., Hijmans E. M., Beelen K., Linn S. C., Gonzalez-Angulo A.M., Stemke-Hale K., Hauptmann M., Beijersbergen R.L., Mills G.B., van de Vijver M.J., Bernards R. A functional genetic approach identifies the P!3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell. 2007;12:395-402.Andre F., Campone M., O'Regan R., Manlius C., Massacesi C., Sahmoud T., Mukhopadhyay P., Soria J.C., Naughton M., Hurvitz S.A. Phase ! study of everolimus plus weekly paclitaxel and trastuzumab in patients with metastatic breast cancer pretreated with trastuzumab. J. Clin. Oncol. 2010;28:5110-15.Morrow P.K., Wulf G.M., Ensor J., Booser D.J., Moore J.A., Flores P.R., Xiong Y., Zhang S., Krop I.E., Winer E.P., Kindelberger D.W., Coviello J., Sahin A.A., Nunez R., Hortobagyi G.N., Yu D., Esteva F.J. Phase I-II study of trastuzumab in combination with everolimus (RAD001) in patients with HER2-overexpressing metasta-tic breast cancer who progressed on trastuzumab-based therapy. J. Clin. Oncol. 2011;29:3126-32.O'Reilly K.E., Rojo F.,She Q.-B.,Solit D.,Mills G.B., Smith D., Lane H., Hofmann F., Hicklin D.J., Ludwig D.L., Baselga J., Rosen N. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res. 2006;66:1500-508.Sledge G.W., Cardoso F., Winer E.P., Piccart M.J. A Dickens tale of the treatment of advanced breast cancer: the past, the present, and the future. ASCO Educational Book. 2012;28-38.Nahta R., Yuan L.X.H., Zhang B., Kobayashi R., Esteva F.J. Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells. Cancer Res. 2005;65:1118-28.Huang X., Gao L., Wang S., McManaman J.L., Thor A.D., Yang X., Esteva F.J., Liu B. Heterotrimerization of the growth factor receptors erbB2, erbB3, and insulin-like growth factor-1 receptor in breast cancer cells resistant to herceptin. Cancer Res. 2010;70: 1204-14.Zhang S., Huang W.-C., Li P., Guo H., Poh S.B., Brady S.W., Xiong Y., Tseng L.M., Li S.H., Ding Z., Sahin A.A., Esteva F.J., Hortobagyi G.N., Yu D. Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways. Nature Medicine. 2011;17:461-69.Garrett J.T., Olivares M.G., Rinehart C., GranjaIngram N.D.,Sanchez V., Chakrabarty A.,Dave B., Cook R.S., Pao W., McKinely E., Manning H.C., Chang J., Arteaga C.L. Transcriptional and post-translational up-regulation of HER3 (ErbB3) compensates for inhibition of the HER2 tyrosine kinase. Proc. Natl. Acad. Sci. USA. 2011;108:5021-26.Garrett J.T., Sutton C.R., Kuba M.G., Cook R.S., Arteaga C.L. Dual blockade of HER2 in HER2-overexpressing tumor cells does not completely eliminate HER3 function. Clin. Can. Res. 2013;19:610-19.Young H., Baum R., Cremerius U., Herholz K., Hoekstra O., Lammertsma A.A., Pruim J., Price P. Measurement of clinical and subclinical tumour response using (18F)-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. Eur. J. Cancer. 1999;35:1773-82.Gamez C., Flamen P., Holmes E., et al. FDGPET/CT for early prediction of response lo neoadjuvant lapatinib, trastuzumab, and their combination in HER2 positive breast cancer patients: the Neo-ALTTO PET study results. Paper presented at: The 2011 European Multidisciplinary Cancer Congress; September 2011 ; Stockholm, Sweden.Горбунова В.А. Новые перспективные препараты для лечения HER2-позитивного рака молочной железы. Фарматека. 2014;8:19-28